Esketamine Nasal Spray More Likely to Provide Treatment-Resistant Depression Remission than Quetiapine

Extended-release quetiapine is commonly used for treatment-resistant depression, but a new study reveals patients receiving esketmanine nasal spray are 54% more likely to reach remission at 8 weeks.

Related Keywords

Reina Benabou ,Andreas Reif ,Janssen Scientific Affairs ,Montgomery Asberg Depression Rating Scale ,